| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.09. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024 | 448 | GlobeNewswire (Europe) | Updated data show consistent objective response rate of 40% and manageable safety profile in patients with non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations... ► Artikel lesen | |
| 14.09. | Black Diamond Therapeutics, Inc: Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) ... | 324 | GlobeNewswire (Europe) | Treatment data were analyzed from 3,276 cases of patients with newly diagnosed EGFR mutant NSCLC from Guardant Health Analyses of patients with non-classical EGFR mutations reveal that the majority... ► Artikel lesen | |
| 14.09. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its ... | 416 | GlobeNewswire (Europe) | Confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) observed in prospectively-selected ACR-368 OncoSignature-positive (BM+) patients with endometrial cancer Achieved statistically significant... ► Artikel lesen | |
| 14.09. | Transgene S.A.: Transgene and BioInvent's Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments | 510 | GlobeNewswire (Europe) | Preliminary data presented at ESMO 2024 demonstrate that BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatment In a patient with a heavily pretreated leiomyosarcoma... ► Artikel lesen | |
| 14.09. | Sutro Biopharma, Inc.: Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024 | 459 | GlobeNewswire (Europe) | - 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in a 56% objective response rate in patients with late-stage ovarian... ► Artikel lesen | |
| 14.09. | Immunocore Holdings plc: Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer | 525 | GlobeNewswire (Europe) | Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Brenetafusp is clinically active as monotherapy and in combination with chemotherapy... ► Artikel lesen | |
| 14.09. | IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer | 495 | GlobeNewswire (Europe) | -- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the Head and Neck Cohort -- -- No New Safety Signals... ► Artikel lesen | |
| 14.09. | Greystone Logistics Inc.: Greystone Logistics Reports Strong Year-End Earnings | 140 | GlobeNewswire (Europe) | TULSA, Okla., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Greystone Logistics, ("Greystone Logistics" or the "Company") (OTCQB:GLGI) the leading manufacturer of recycled plastic pallets providing sustainable... ► Artikel lesen | |
| 14.09. | VERSES AI Inc. Announces 2024 AGSM Results | 628 | GlobeNewswire (Europe) | VANCOUVER, British Columbia, Sept. 13, 2024 (GLOBE NEWSWIRE) -- VERSES AI Inc. (the "Company" or "VERSES") (CBOE Canada: VERS) (OTCQX: VRSSF) is pleased to announce the results of the Annual General... ► Artikel lesen | |
| 14.09. | NuCana plc: NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024 | 440 | GlobeNewswire (Europe) | Combination of NUC-7738 plus Pembrolizumab Resulted in Prolonged Progression Free Survival, a Compelling Disease Control Rate including Partial Responses, and a Favorable Safety ProfileBARCELONA, Spain... ► Artikel lesen | |
| 14.09. | Avacta Group: Avacta Reports Updated Phase 1 Clinical Data of AVA6000 at the European Society for Medical Oncology (ESMO) Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors | 442 | GlobeNewswire (Europe) | This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act... ► Artikel lesen | |
| 14.09. | iTeos Therapeutics Inc. Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients | 622 | GlobeNewswire (Europe) | - Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose- >30% cORR difference between... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| SUPER MICRO COMPUTER | 3.970 |
| EVOTEC | 3.171 |
| TUI | 2.794 |
| NVIDIA | 2.721 |
| BAYER | 2.653 |
| NEL | 2.456 |
| RENK GROUP | 1.783 |
| RHEINMETALL | 1.702 |
| TESLA | 1.298 |
| PALANTIR TECHNOLOGIES | 1.270 |
| VOLKSWAGEN | 1.259 |
| DEUTSCHE BANK | 1.143 |
| PLUG POWER | 1.063 |
| AMAZON | 1.039 |
| BYD | 1.038 |
| MICROSTRATEGY | 1.038 |
| PROSIEBENSAT.1 | 1.023 |
| BASF | 1.017 |
| COMMERZBANK | 1.014 |
| MERCEDES-BENZ | 945 |
| THYSSENKRUPP | 934 |
| JINKOSOLAR | 883 |
| ALLIANZ | 882 |
| AIXTRON SE | 875 |
| DEUTSCHE TELEKOM | 872 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
